A small desk with a strict standard.
Aminoscope is an independent research desk covering peptides, GLP-1 medications, and longevity therapeutics. We exist because the gap between what the trials say and what the internet says about these molecules is enormous — and consequential.
Aminoscope is published by MEAS Partners, LLC. Our writers publish under consistent pen names — a common practice in health and science journalism — so that the work is judged on its sourcing rather than on personality. Bylines are stable: the same name always means the same writer, and every claim is anchored to a citation you can check yourself.
Medical and scientific accuracy is verified against primary sources before anything is published. For clinical content we are building a panel of licensed reviewers; review status is stated honestly on each piece, and we never attach credentials we cannot stand behind.
The desk
Julian Roth
Research & dataTrials, effect sizes, and the primary literature.
View profile →Nadia Feldman
Access & costCost, coverage, access pathways, and side-effect timelines.
View profile →Priya Anand
Pharmacology & mechanismsReceptors, half-lives, drug interactions, and where mechanism outruns evidence.
View profile →Theo Lindqvist
Peptides & longevityPeptides, NAD+, senolytics, and healthspan — graded by human evidence.
View profile →Read more about how we work in our methodology and disclosures.